




RealRate

PHARMACEUTICAL 2017

Nabriva Therapeutics plc
Rank 107 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Nabriva Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nabriva Therapeutics plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Nabriva Therapeutics plc is the variable Other Expenses, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 63% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	90,621
Cost of Goods Sold	0
Intangible Assets	270
Liabilities, Current	15,877
Liabilities, Non-Current	107
Other Assets	1,830
Other Compr. Net Income	50
Other Expenses	47,397
Other Liabilities	0
Other Net Income	6,042
Other Revenues	0
Property and Equipment	519
Research and Development	0
Selling, General and Administrative Expense	13,535

Output Variable	Value in 1000 USD
Assets	93,240
Liabilities	15,984
Expenses	60,932
Revenues	0
Stockholders Equity	77,256
Net Income	-54,890
Comprehensive Net Income	-54,865
BaseVar	88,124
ECR before LimitedLiability	208%
Economic Capital Ratio	308%